Skip to main content

Table 2 Normal tissue dose constraints

From: Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG)

Organs

Dose constraints

Remnant stomach

V40 < 50% (no hot spot)

Liver

V30 < 40%

Dmean < 18Gy

Kidney

V20 < 30%

Lung

V20 < 20%

Heart

V30 < 30%

Intestine

Dmax ≤ 50Gy

Spinal cord

Dmax < 40 Gy

Back to article page

Trials

ISSN: 1745-6215